Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARMP Armata Pharmaceuticals	$2.54 +3.7%	$2.12	$0.90 ▼ $2.96	$91.93M	0.99	13,125 shs	2,245 shs
AURA Aura Biosciences	$6.74 -2.2%	$6.48	$4.34 ▼ $12.38	$338.81M	0.46	154,595 shs	200,596 shs
FHTX Foghorn Therapeutics	$4.99 -5.0%	$5.05	$2.94 ▼ $10.25	$278.15M	3.05	112,799 shs	171,664 shs
PVLA Palvella Therapeutics	$36.55 -0.1%	$27.01	$11.17 ▼ $40.50	$404.10M	-0.02	173,996 shs	56,129 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARMP Armata Pharmaceuticals	+3.67%	+6.28%	+30.93%	+76.74%	-30.60%
AURA Aura Biosciences	-2.18%	-6.78%	+4.33%	+9.59%	-33.99%
FHTX Foghorn Therapeutics	-4.95%	-19.39%	+0.81%	+17.69%	-28.92%
PVLA Palvella Therapeutics	-0.08%	-5.36%	+53.38%	+49.43%	+3,654,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARMP Armata Pharmaceuticals	2.2025 of 5 stars	3.5	5.0	0.0	1.7	0.0
AURA Aura Biosciences	1.5397 of 5 stars	3.6	0.0	0.6	3.3	0.0
FHTX Foghorn Therapeutics	2.4912 of 5 stars	3.6	4.0	0.6	1.7	0.6
PVLA Palvella Therapeutics	2.6773 of 5 stars	3.6	0.0	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARMP Armata Pharmaceuticals	3.00	Buy	$9.00	254.33% Upside
AURA Aura Biosciences	3.25	Buy	$22.00	226.41% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	142.99% Upside
PVLA Palvella Therapeutics	3.11	Buy	$47.50	29.96% Upside

Current Analyst Ratings Breakdown

Latest ARMP, PVLA, AURA, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	PVLA Palvella Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$56.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/19/2025	ARMP Armata Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARMP Armata Pharmaceuticals	$5.17M	17.78	N/A	N/A	($1.33) per share	-1.91
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
FHTX Foghorn Therapeutics	$22.60M	12.31	N/A	N/A	($0.82) per share	-6.09
PVLA Palvella Therapeutics	$42.81M	9.44	N/A	N/A	$5.58 per share	6.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARMP Armata Pharmaceuticals	-$18.92M	-$1.64	N/A	N/A	N/A	N/A	N/A	-25.06%	8/12/2025 (Estimated)
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	0.00	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)

Latest ARMP, PVLA, AURA, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AURA Aura Biosciences	-$0.47	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	FHTX Foghorn Therapeutics	-$0.32	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	PVLA Palvella Therapeutics	-$0.81	N/A	N/A	N/A	N/A	N/A
8/12/2025	N/A	ARMP Armata Pharmaceuticals	-$0.39	N/A	N/A	N/A	$1.38 million	N/A
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARMP Armata Pharmaceuticals	N/A	0.12	0.12
AURA Aura Biosciences	N/A	11.06	11.06
FHTX Foghorn Therapeutics	N/A	3.16	3.16
PVLA Palvella Therapeutics	N/A	8.84	8.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARMP Armata Pharmaceuticals	3.57%
AURA Aura Biosciences	96.75%
FHTX Foghorn Therapeutics	61.55%
PVLA Palvella Therapeutics	40.11%

Insider Ownership

Company	Insider Ownership
ARMP Armata Pharmaceuticals	84.50%
AURA Aura Biosciences	5.40%
FHTX Foghorn Therapeutics	7.58%
PVLA Palvella Therapeutics	20.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARMP Armata Pharmaceuticals	70	36.19 million	5.61 million	Not Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A

ARMP, PVLA, AURA, and FHTX Headlines

Recent News About These Companies

Royce & Associates LP Invests $2 Million in Palvella Therapeutics, Inc. (NASDAQ:PVLA)

July 29, 2025 | marketbeat.com

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of "Buy" from Brokerages

July 28, 2025 | marketbeat.com

Truist Financial Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA)

July 23, 2025 | americanbankingnews.com

Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Truist Financial

July 21, 2025 | marketbeat.com

PVLA - Palvella Therapeutics Inc Sustainability - Morningstar

July 9, 2025 | morningstar.comM

Palvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN Rapamycin

July 9, 2025 | msn.com

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by Analysts

July 3, 2025 | marketbeat.com

Palvella Therapeutics, Inc. Added to Russell 3000® and Russell 2000® Indexes as of June 30, 2025

June 30, 2025 | quiverquant.comQ

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

June 30, 2025 | globenewswire.com

PVLA - Palvella Therapeutics Inc Key Metrics - Morningstar

June 27, 2025 | morningstar.comM

PVLA - Palvella Therapeutics Inc Executives - Morningstar

June 26, 2025 | morningstar.comM

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% | The ...

June 24, 2025 | manilatimes.netM

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by ... - Morningstar

June 24, 2025 | morningstar.comM

Palvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026 - Nasdaq

June 24, 2025 | nasdaq.com

Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin

June 24, 2025 | msn.com

Palvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026

June 23, 2025 | quiverquant.comQ

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

June 23, 2025 | globenewswire.com

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

June 18, 2025 | globenewswire.com

Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin

June 13, 2025 | msn.com

Palvella Therapeutics Secures FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ for Microcystic Lymphatic Malformations

June 9, 2025 | quiverquant.comQ

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

June 9, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
3 Fast Food Stocks That Won’t Give You Indigestion Right Now
By Brian O'Connell | July 16, 2025
View 3 Fast Food Stocks That Won’t Give You Indigestion Right Now
How Texas Roadhouse Is Winning in a Changing Consumer Market
By Dan Schmidt | July 14, 2025
View How Texas Roadhouse Is Winning in a Changing Consumer Market
Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]
By MarketBeat Staff | July 29, 2025
View Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]

ARMP, PVLA, AURA, and FHTX Company Descriptions

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$2.54 +0.09 (+3.67%)

Closing price 08/1/2025 04:10 PM Eastern

Extended Trading

$2.50 -0.04 (-1.57%)

As of 08/1/2025 04:56 PM Eastern

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Aura Biosciences NASDAQ:AURA

$6.74 -0.15 (-2.18%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.74 0.00 (0.00%)

As of 08/1/2025 05:01 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Foghorn Therapeutics NASDAQ:FHTX

$4.99 -0.26 (-4.95%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.96 -0.03 (-0.50%)

As of 08/1/2025 05:57 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Palvella Therapeutics NASDAQ:PVLA

$36.55 -0.03 (-0.08%)

As of 08/1/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time